The impact of health care settings on survival time of patients with chronic myeloid leukemia-Reference-Cited by-同舟云学术

The impact of health care settings on survival time of patients with chronic myeloid leukemia

Published:2014-04-17 Issue:16 Volume:123 Page:2494-2496
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Lauseker Michael¹,Hasford Joerg¹,Pfirrmann Markus¹,Hehlmann Rüdiger²

Affiliation:

1. Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität, München, Germany; and

2. III. Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany

Abstract

Key Points CML patients enjoyed superior survival chances when treated in THs. Treatment centers having less experience with CML patients did not affect the patient’s survival chances.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/16/2494/1375937/2494.pdf

Reference6 articles.

1. Does academic medicine matter?;Clark;PLoS Med,2006

2. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.;Hehlmann;J Clin Oncol,2011

3. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV.;Hehlmann;J Clin Oncol,2014

4. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.;Hasford;Blood,2011

5. Patient outcomes with teaching versus nonteaching healthcare: a systematic review.;Papanikolaou;PLoS Med,2006

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors;Leukemia;2021-05-17

2. Epidemiology of Chronic Myeloid Leukaemia;Hematologic Malignancies;2021

3. Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia;Leukemia & Lymphoma;2020-10-15

4. Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center;Clinical Lymphoma Myeloma and Leukemia;2020-06

5. Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: Results from a population‐based study;European Journal of Haematology;2019-08-28